IV Deployment Of cSVF In Sterile Normal Saline IV Solution ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
85	Idiopathic interstitial pneumonia	1
229	Autoimmune pulmonary alveolar proteinosis	1

85. Idiopathic interstitial pneumonia

Clinical trials : 598 / Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04326036 (ClinicalTrials.gov)	March 25, 2020	26/3/2020	Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection	Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection	Pulmonary Alveolar Proteinosis;COPD;Idiopathic Pulmonary Fibrosis;Viral Pneumonia;Coronavirus Infection;Interstitial Lung Disease	Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF);Device: Centricyte 1000;Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution;Drug: Liberase Enzyme (Roche);Drug: Sterile Normal Saline for Intravenous Use	Black Tie Medical, Inc.	Robert W. Alexander, MD	Enrolling by invitation	18 Years	90 Years	All	10	Early Phase 1	United States

Clinical trials : 43 / Drugs : 34 - (DrugBank : 8) / Drug target genes : 3 - Drug target pathways : 14

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04326036 (ClinicalTrials.gov)	March 25, 2020	26/3/2020	Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection	Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection	Pulmonary Alveolar Proteinosis;COPD;Idiopathic Pulmonary Fibrosis;Viral Pneumonia;Coronavirus Infection;Interstitial Lung Disease	Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF);Device: Centricyte 1000;Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution;Drug: Liberase Enzyme (Roche);Drug: Sterile Normal Saline for Intravenous Use	Black Tie Medical, Inc.	Robert W. Alexander, MD	Enrolling by invitation	18 Years	90 Years	All	10	Early Phase 1	United States